Target Discovery
Novel druggable targets surfaced by the OmicsOS Hypothesis Agent, which integrates the Apollo multi-omics layer (scRNA-seq, WGS/WES, spatial, proteomics) with the literature and ranks candidate targets by druggability, disease association, and India-specific genetic signals. The output is not a list — it is a typed, provenance-signed hypothesis graph ready for downstream prioritization.
What we deliver
Disease-specific target ranking
A ranked list of candidate targets per indication with druggability scores, novelty scores, and confidence intervals. Each target traceable back to the multi-omics evidence and Apollo cohort it was derived from.
India-specific target intelligence
Targets emerging from Indian-population genetics — novel fusions in oral cancer, NAFLD subtypes, CV / metabolic comorbidities. These do not surface in TCGA / UK Biobank because the variants are not common there.
Target dossiers (CDSCO-ready)
For each prioritized target, a regulatory-grade dossier covering mechanism, supporting evidence, competitive landscape, biomarker hooks, and patentability assessment.
Wet-lab validation handoff
Every target ships with a recommended validation experiment graph (knockdown, CRISPR screen, target-engagement assay) that the LabOS Execution Broker can route to a CRO partner the same week.
Differentiator vs. Western target ID
Most target-ID engagements (BenevolentAI, Insilico, Lantern) draw from US/EU genomic data — by design they cannot surface India-population signals. Our Apollo cohort makes us structurally complementary to, not a competitor of, those platforms; pharma partners typically license both.
Engagement
$0.5M–$1.5M per indication. Typical engagement: 3–6 months, ending with a ranked target list, two top-target dossiers, and a wet-lab validation plan ready to execute.
Example · oral cancer indication
Week 1–4
Integrate Apollo oral cancer scRNA + WGS cohort. Hypothesis Agent ranks 12 targets; 3 carry India-enriched fusion signatures.
Week 5–8
Top 2 targets receive CDSCO-ready dossiers with competitive landscape and druggability scores.
Week 9–12
Validation DAG routed to Syngene — CRISPR knockdown + target-engagement assay. Results feed Learning Agent for next program.